Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Breast Cancer

  Free Subscription


02.04.2018

1 Am J Surg
1 Ann Surg Oncol
8 Anticancer Res
7 BMC Cancer
2 Br J Cancer
1 Breast Cancer
1 Breast Cancer (Dove Med Press)
5 Breast Cancer Res
6 Breast Cancer Res Treat
1 Breast J
1 Cancer
1 Cancer Chemother Pharmacol
2 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
3 Cancer Res
4 Clin Breast Cancer
2 Clin Cancer Res
3 Eur J Cancer
1 Exp Cell Res
1 Histopathology
5 Int J Cancer
1 Int J Oncol
2 J Clin Oncol
2 J Nucl Med
2 J Surg Oncol
6 N Engl J Med
1 NPJ Breast Cancer
6 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg

  1. COOK M, Johnson N
    Pre-surgical chemotherapy for breast cancer may be associated with improved outcomes.
    Am J Surg. 2018 Mar 16. pii: S0002-9610(17)31537.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. DE MELO GAGLIATO D, Chavez-MacGregor M
    Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?
    Ann Surg Oncol. 2018 Mar 29. pii: 10.1245/s10434-018-6415.
    PubMed     Text format    


    Anticancer Res

  3. ORSARIA P, Caredda E, Genova F, Materazzo M, et al
    Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
    Anticancer Res. 2018;38:2109-2117.
    PubMed     Text format     Abstract available

  4. JUZENIENE A, Bernoulli J, Suominen M, Halleen J, et al
    Antitumor Activity of Novel Bone-seeking, alpha-emitting (224)Ra-solution in a Breast Cancer Skeletal Metastases Model.
    Anticancer Res. 2018;38:1947-1955.
    PubMed     Text format     Abstract available

  5. UEMATSU N, Zhao Y, Kiyomi A, Yuan BO, et al
    Chemo-sensitivity of Two-dimensional Monolayer and Three-dimensional Spheroid of Breast Cancer MCF-7 Cells to Daunorubicin, Docetaxel, and Arsenic Disulfide.
    Anticancer Res. 2018;38:2101-2108.
    PubMed     Text format     Abstract available

  6. HSIAO CL, Liu LC, Shih TC, Chuang CL, et al
    The Association of Matrix Metalloproteinase-8 Promoter Genotypes in Breast Cancer.
    Anticancer Res. 2018;38:2181-2185.
    PubMed     Text format     Abstract available

  7. TUOHINEN SS, Keski-Pukkila K, Skytta T, Huhtala H, et al
    Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer.
    Anticancer Res. 2018;38:2207-2215.
    PubMed     Text format     Abstract available

  8. TAKADA K, Kashiwagi S, Goto W, Asano Y, et al
    Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:2285-2294.
    PubMed     Text format     Abstract available

  9. ASANO Y, Kashiwagi S, Goto W, Takada K, et al
    Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Anticancer Res. 2018;38:2311-2321.
    PubMed     Text format     Abstract available

  10. INOUE Y, Yamashita N, Ueo H, Tanaka K, et al
    The Clinical Usefulness of the LigaSure Small Jaw in Axillary Lymph Node Dissection in Patients with Breast Cancer.
    Anticancer Res. 2018;38:2359-2362.
    PubMed     Text format     Abstract available


    BMC Cancer

  11. XU Y, Yang X, Wang T, Yang L, et al
    Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-gamma-linolenic acid peroxidation dependent mechanism.
    BMC Cancer. 2018;18:330.
    PubMed     Text format     Abstract available

  12. BRONTE G, Rocca A, Ravaioli S, Puccetti M, et al
    Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    BMC Cancer. 2018;18:348.
    PubMed     Text format     Abstract available

  13. WANG YA, Jian JW, Hung CF, Peng HP, et al
    Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    BMC Cancer. 2018;18:315.
    PubMed     Text format     Abstract available

  14. CHEN J, Zhu Y, Zhang W, Peng X, et al
    Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells.
    BMC Cancer. 2018;18:342.
    PubMed     Text format     Abstract available

  15. AN X, Xu F, Luo R, Zheng Q, et al
    The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
    BMC Cancer. 2018;18:331.
    PubMed     Text format     Abstract available

  16. DITTUS KL, Harvey JR, Bunn JY, Kokinda ND, et al
    Impact of a behaviorally-based weight loss intervention on parameters of insulin resistance in breast cancer survivors.
    BMC Cancer. 2018;18:351.
    PubMed     Text format     Abstract available

  17. AHN SG, Cha YJ, Bae SJ, Yoon C, et al
    Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
    BMC Cancer. 2018;18:320.
    PubMed     Text format     Abstract available


    Br J Cancer

  18. QUIROS-GONZALEZ I, Tomaszewski MR, Aitken SJ, Ansel-Bollepalli L, et al
    Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry.
    Br J Cancer. 2018 Mar 26. pii: 10.1038/s41416-018-0033.
    PubMed     Text format     Abstract available

  19. JOSEPH C, Macnamara O, Craze M, Russell R, et al
    Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
    Br J Cancer. 2018 Mar 28. pii: 10.1038/s41416-018-0041.
    PubMed     Text format     Abstract available


    Breast Cancer

  20. SASADA S, Shien T, Iwata H
    Current status of postmastectomy radiation therapy in T1-2 breast cancer with limited positive lymph nodes in Japan: Japan Clinical Oncology Group Survey.
    Breast Cancer. 2018 Mar 23. pii: 10.1007/s12282-018-0855.
    PubMed     Text format    


    Breast Cancer (Dove Med Press)


  21. Erratum: Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum].
    Breast Cancer (Dove Med Press). 2018;10:51.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  22. TANG YC, Ho SC, Tan E, Ng AWT, et al
    Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
    Breast Cancer Res. 2018;20:22.
    PubMed     Text format     Abstract available

  23. EL ANSARI R, Craze ML, Miligy I, Diez-Rodriguez M, et al
    The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
    Breast Cancer Res. 2018;20:21.
    PubMed     Text format     Abstract available

  24. FROELUNDE AS, Ohlenbusch M, Hansen KB, Jessen N, et al
    Murine breast cancer feed arteries are thin-walled with reduced alpha1A-adrenoceptor expression and attenuated sympathetic vasocontraction.
    Breast Cancer Res. 2018;20:20.
    PubMed     Text format     Abstract available

  25. KNIGHT JA, Blackmore KM, Fan J, Malone KE, et al
    The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study.
    Breast Cancer Res. 2018;20:23.
    PubMed     Text format     Abstract available

  26. ZEIDAN B, Manousopoulou A, Garay-Baquero DJ, White CH, et al
    Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study.
    Breast Cancer Res. 2018;20:19.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  27. PHILLIPS M, Cataneo RN, Cruz-Ramos JA, Huston J, et al
    Prediction of breast cancer risk with volatile biomarkers in breath.
    Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4764.
    PubMed     Text format     Abstract available

  28. CAI H, Guo W, Zhang S, Li N, et al
    A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
    Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4758.
    PubMed     Text format     Abstract available

  29. BHAT RR, Yadav P, Sahay D, Bhargava DK, et al
    GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.
    Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4751.
    PubMed     Text format     Abstract available

  30. CHOWDHURY M, Euhus D, Arun B, Umbricht C, et al
    Validation of a personalized risk prediction model for contralateral breast cancer.
    Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4763.
    PubMed     Text format     Abstract available

  31. MUNZONE E, Gray KP, Fumagalli C, Guerini-Rocco E, et al
    Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
    Breast Cancer Res Treat. 2018 Mar 27. pii: 10.1007/s10549-018-4767.
    PubMed     Text format     Abstract available

  32. HILL DA, Friend S, Lomo L, Wiggins C, et al
    Breast cancer survival, survival disparities, and guideline-based treatment.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4761.
    PubMed     Text format     Abstract available


    Breast J

  33. YOON HJ, Kim Y, Chung J, Kim BS, et al
    Predicting neo-adjuvant chemotherapy response and progression-free survival of locally advanced breast cancer using textural features of intratumoral heterogeneity on F-18 FDG PET/CT and diffusion-weighted MR imaging.
    Breast J. 2018 Mar 30. doi: 10.1111/tbj.13032.
    PubMed     Text format     Abstract available


    Cancer

  34. UEMURA MI, French JT, Hess KR, Liu D, et al
    Development of CNS metastases and survival in patients with inflammatory breast cancer.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31336.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  35. KIMURA K, Iwamoto M, Tanaka S, Yamamoto D, et al
    A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
    Cancer Chemother Pharmacol. 2018 Mar 28. pii: 10.1007/s00280-018-3567.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  36. HOWLADER N, Cronin KA, Kurian AW, Andridge R, et al
    Differences in Breast Cancer Survival by Molecular Subtypes in the United States.
    Cancer Epidemiol Biomarkers Prev. 2018 Mar 28. pii: 1055-9965.EPI-17-0627.
    PubMed     Text format     Abstract available

  37. BRANTLEY KD, Kjaersgaard A, Cronin-Fenton D, Yacoub R, et al
    Stanniocalcin expression as a predictor of late breast cancer recurrence.
    Cancer Epidemiol Biomarkers Prev. 2018 Mar 28. pii: 1055-9965.EPI-17-0905.
    PubMed     Text format     Abstract available


    Cancer Lett

  38. LAWSON JS, Salmons B, Gunzburg WH
    Commentary regarding Gannon et al. "Viral infections and breast cancer - A current perspective".
    Cancer Lett. 2018;424:117-118.
    PubMed     Text format    

  39. LI D, Wang H, Ding Y, Zhang Z, et al
    Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis.
    Cancer Lett. 2018;424:97-108.
    PubMed     Text format     Abstract available


    Cancer Res

  40. WANG LH, Tseng CW, Kuo WH, Chan SH, et al
    Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
    Cancer Res. 2018 Mar 29. pii: 0008-5472.CAN-17-2906.
    PubMed     Text format     Abstract available

  41. REN D, Zhu X, Kong R, Zhao Z, et al
    Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.
    Cancer Res. 2018 Mar 22. pii: 0008-5472.CAN-17-2994.
    PubMed     Text format     Abstract available

  42. ZHANG B, Chen MY, Sheng YJ, Zhuo XB, et al
    A large-scale, exome-wide association study of Han Chinese women identifies three novel loci predisposing to breast cancer.
    Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-1721.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  43. MUTSCHLER NS, Scholz C, Friedl TWP, Zwingers T, et al
    Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
    Clin Breast Cancer. 2018;18:175-183.
    PubMed     Text format     Abstract available

  44. MEATTINI I, Pezzulla D, Saieva C, Bernini M, et al
    Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study.
    Clin Breast Cancer. 2018 Mar 2. pii: S1526-8209(18)30015.
    PubMed     Text format     Abstract available

  45. RAO N, Chen K, Yang Q, Niu J, et al
    Proof-of-Concept Study of 3-D-Printed Mold-Guided Breast-Conserving Surgery in Breast Cancer Patients.
    Clin Breast Cancer. 2018 Feb 20. pii: S1526-8209(18)30039.
    PubMed     Text format     Abstract available

  46. MIYAGAWA Y, Araki K, Bun A, Ozawa H, et al
    Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
    Clin Breast Cancer. 2018 Mar 8. pii: S1526-8209(17)30724.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  47. AFGHAHI A, Purington N, Han SS, Desai M, et al
    Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
    Clin Cancer Res. 2018 Mar 26. pii: 1078-0432.CCR-17-1323.
    PubMed     Text format     Abstract available

  48. WARD E, Vareslija D, Charmsaz S, Fagan A, et al
    Epigenome-wide SRC-1 mediated gene silencing represses cellular differentiation in advanced breast cancer.
    Clin Cancer Res. 2018 Mar 22. pii: 1078-0432.CCR-17-2615.
    PubMed     Text format     Abstract available


    Eur J Cancer

  49. ETHIER JL, Ocana A, Rodriguez Lescure A, Ruiz A, et al
    Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
    Eur J Cancer. 2018;94:199-205.
    PubMed     Text format     Abstract available

  50. RUIZ A, van Hillegersberg R, Siesling S, Castro-Benitez C, et al
    Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison.
    Eur J Cancer. 2018;95:1-10.
    PubMed     Text format     Abstract available

  51. ROBERTSON JFR, Cheung KL, Noguchi S, Shao Z, et al
    Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
    Eur J Cancer. 2018;94:206-215.
    PubMed     Text format     Abstract available


    Exp Cell Res

  52. LI C, Fan Q, Quan H, Nie M, et al
    The three branches of the unfolded protein response exhibit differential significance in breast cancer growth and stemness.
    Exp Cell Res. 2018 Mar 27. pii: S0014-4827(18)30183.
    PubMed     Text format     Abstract available


    Histopathology

  53. ALFARSI L, Johnston S, Liu DX, Rakha E, et al
    Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer.
    Histopathology. 2018 Mar 30. doi: 10.1111/his.13523.
    PubMed     Text format     Abstract available


    Int J Cancer

  54. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    A dietary pattern based on estrogen metabolism is associated with breast cancer risk in a prospective cohort of postmenopausal women.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31387.
    PubMed     Text format     Abstract available

  55. DE MUNCK L, Fracheboud J, de Bock GH, den Heeten GJ, et al
    Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program?
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31388.
    PubMed     Text format     Abstract available

  56. YUE W, Wang J, Atkins KA, Bottalico L, et al
    Effect of a tissue selective estrogen complex (TSEC) on breast cancer: Role of unique properties of conjugated equine estrogen.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31401.
    PubMed     Text format     Abstract available

  57. ERIKSSON L, Bergh J, Humphreys K, Warnberg F, et al
    Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study.
    Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31411.
    PubMed     Text format     Abstract available

  58. GUO W, Key TJ, Reeves GK
    Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31394.
    PubMed     Text format     Abstract available


    Int J Oncol

  59. WU T, Song H, Xie D, Zhao B, et al
    Silencing of ASPP2 promotes the proliferation, migration and invasion of triple-negative breast cancer cells via the PI3K/AKT pathway.
    Int J Oncol. 2018 Mar 20. doi: 10.3892/ijo.2018.4331.
    PubMed     Text format     Abstract available


    J Clin Oncol

  60. HERSHMAN DL, Till C, Shen S, Wright JD, et al
    Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.
    J Clin Oncol. 2018 Mar 27:JCO2017774414. doi: 10.1200/JCO.2017.77.4414.
    PubMed     Text format     Abstract available

  61. MASSARWEH SA, Sledge GW, Miller DP, McCullough D, et al
    Molecular Characterization and Mortality From Breast Cancer in Men.
    J Clin Oncol. 2018 Mar 27:JCO2017768861. doi: 10.1200/JCO.2017.76.8861.
    PubMed     Text format     Abstract available


    J Nucl Med

  62. MONTEMAGNO C, Bacot S, Ahmadi M, Kerfelec B, et al
    Preclinical evaluation of novel mesothelin-specific ligands for SPECT imaging of Triple Negative Breast Cancer.
    J Nucl Med. 2018 Mar 23. pii: jnumed.117.203489. doi: 10.2967/jnumed.117.203489.
    PubMed     Text format     Abstract available

  63. NIENHUIS HH, van Kruchten M, Elias SG, Glaudemans AWJM, et al
    ((18))F-fluoroestradiol Tumor Uptake is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.198846. doi: 10.2967/jnumed.117.198846.
    PubMed     Text format     Abstract available


    J Surg Oncol

  64. ALTUNDAG K
    Breast cancer subtypes and local recurrence rate after surgery for bone metastasis to the extremities.
    J Surg Oncol. 2018 Mar 30. doi: 10.1002/jso.24987.
    PubMed     Text format    

  65. FOSTER D, Choy N, Porter C, Ahmed S, et al
    Axillary reverse mapping with indocyanine green or isosulfan blue demonstrate similar crossover rates to radiotracer identified sentinel nodes.
    J Surg Oncol. 2018;117:336-340.
    PubMed     Text format     Abstract available


    N Engl J Med


  66. Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-1266.
    PubMed     Text format    

  67. SCHWARZ EB, Foster DG, Grossman D
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-4.
    PubMed     Text format    

  68. WOOD S
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    PubMed     Text format    

  69. ROBERTS K, Merkatz RB, Vieira CS
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    PubMed     Text format    

  70. CRAMER DW, Braaten K
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264-8.
    PubMed     Text format    

  71. NACHTIGALL L, Naftolin F, Keefe DL
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1265.
    PubMed     Text format    


    NPJ Breast Cancer

  72. FOY KC, Fisher JL, Lustberg MB, Gray DM, et al
    Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women.
    NPJ Breast Cancer. 2018;4:7.
    PubMed     Text format     Abstract available


    PLoS One

  73. NGUYEN CP, Adang EMM
    Cost-effectiveness of breast cancer screening using mammography in Vietnamese women.
    PLoS One. 2018;13:e0194996.
    PubMed     Text format     Abstract available

  74. KHAJAH MA, Mathew PM, Luqmani YA
    Na+/K+ ATPase activity promotes invasion of endocrine resistant breast cancer cells.
    PLoS One. 2018;13:e0193779.
    PubMed     Text format     Abstract available

  75. TAMEZ-PENA JG, Rodriguez-Rojas JA, Gomez-Rueda H, Celaya-Padilla JM, et al
    Radiogenomics analysis identifies correlations of digital mammography with clinical molecular signatures in breast cancer.
    PLoS One. 2018;13:e0193871.
    PubMed     Text format     Abstract available

  76. ARYAL B, Rao VA
    Specific protein carbonylation in human breast cancer tissue compared to adjacent healthy epithelial tissue.
    PLoS One. 2018;13:e0194164.
    PubMed     Text format     Abstract available

  77. DVORAK KM, Pettee KM, Rubinic-Minotti K, Su R, et al
    Carcinoma associated fibroblasts (CAFs) promote breast cancer motility by suppressing mammalian Diaphanous-related formin-2 (mDia2).
    PLoS One. 2018;13:e0195278.
    PubMed     Text format     Abstract available

  78. BROMBERG SE, Moraes PRAF, Ades F
    Correction: Prime incision: A minimally invasive approach to breast cancer surgical treatment-A 2 cohort retrospective comparison with conventional breast conserving surgery.
    PLoS One. 2018;13:e0195130.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  79. KE H, Zhao L, Zhang H, Feng X, et al
    Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3.
    Proc Natl Acad Sci U S A. 2018 Mar 26. pii: 1714573115.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: